Kíral Launches Research-Forward Peptide Care, Pairing Physician Supervision with Longitudinal Patient Research

Smiling man in glasses working on a laptop in an office lobby

FOR IMMEDIATE RELEASE

Austin-based telehealth company opens to patients with licensed providers, 503A pharmacy sourcing and IRB-approved research

AUSTIN, Texas, Nov. 17, 2026 – Kíral Sciences today launched Kíral Peptides, a telehealth company offering personalized, physician-supervised peptide and therapeutics care. Kíral pairs licensed providers with research: patients can track their biomarkers and health data over time and, with consent, contribute to an IRB-approved longitudinal study of how these therapies perform in real life.

Interest in peptides has grown quickly, much of it driven by forums, influencers and unregulated sellers. Kíral was built to bring that interest into a clinical setting, where a licensed provider reviews each patient’s history, sets the dose and follows up over time. Every treatment is sourced from licensed 503A compounding pharmacies.

Kíral’s formulary spans metabolic health, longevity, sexual health, cognition, performance and recovery. Patients begin with an online intake and a telehealth visit with a licensed provider, who determines whether a treatment is appropriate. Kíral recommends a baseline lab panel so patients and providers can track progress with real data.

“I came to peptides as a patient before I came to them as a founder,” said David Rivera, CEO and Co-Founder of Kíral. “I’ve watched too many people get rushed through care for long-term health needs. We built Kíral so patients have providers who take the time to understand them, and so all of us can learn what really works from real outcomes.”

“There is real scientific promise in this space, and far too little rigorous data,” said Dr. Rachele Pojednic, Science Advisor and Co-Founder of Kíral.

Kíral was founded by four co-founders with more than 50 years of combined experience across clinical care, longevity research, telehealth and medical operations: David Rivera (CEO and Co-Founder), Dr. Rachele Pojednic (Science Advisor and Co-Founder), Alexandra “Lexi” Siojo, NP (Clinical Advisor and Co-Founder) and Nikita “Niki” Patel (Chief Operating Officer and Co-Founder).

Dr. Pojednic will also appear on the WHOOP podcast during launch week, discussing peptides, what the research shows so far, and why Kíral was built around real-world evidence.

Kíral is opening with limited capacity in the U.S., with plans to expand internationally. The first 50 patients receive onboarding at no cost, and Kíral will offer additional promotions through Thanksgiving and the holiday season. Learn more at trykiral.com.

About Kíral

Kíral Sciences, Inc. is an Austin-based, research-forward telehealth company delivering personalized peptide and therapeutics care under licensed provider supervision. Its name comes from chirality, the principle that a molecule’s structure determines its function. Learn more at trykiral.com.